Artiva Biotherapeutics, Inc.ARTVNASDAQ
Loading
Year-over-year research & development expense growth
Latest
4.04%
↑ 72% vs avg
Percentile
P55
Within normal range
Streak
1 qtr
Consecutive growthAccelerating
Average
2.35%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 4.04% |
| Q3 2025 | -4.98% |
| Q2 2025 | 4.74% |
| Q1 2025 | 28.05% |
| Q4 2024 | -1.53% |
| Q3 2024 | 9.66% |
| Q2 2024 | 10.55% |
| Q1 2024 | 0.03% |
| Q4 2023 | -14.63% |
| Q3 2023 | 16.01% |
| Q2 2023 | -23.76% |
| Q1 2023 | 0.00% |